{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T03:33:44Z","timestamp":1764646424672,"version":"3.37.3"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective(s)<\/jats:title>\n                  <jats:p>Chronic kidney disease (CKD) is an insidious disease that requires early nephroprotective measures to delay progression to end-stage kidney disease. The objective of this study was to describe the management of patients with CKD in primary care, including clinical and biological monitoring and prescribed treatments. A retrospective, single-centre study was conducted on adult patients who were treated in the Maison de Neufch\u00e2tel (France) between 2012 and 2017 at least once a year. The inclusion criteria were 2 estimated glomerular filtration rate (eGFR) measurements &amp;lt;60 mL\/min more than 3 months apart. Two subgroups were constituted according to whether CKD was coded in the electronic medical records (EMRs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 291 (6.7%, CI95% 5.9\u20137.4) patients with CKD were included. The mean eGFR was 51.0 \u00b1 16.4 mL\/min. Hypertension was the most frequent health problem reported (n = 93, 32%). Nephrotective agents were prescribed in 194 (66.7%) patients, non-steroidal anti-inflammatory drugs (NSAIDs) in 22 (8%) patients, and proton-pump inhibitors (PPIs) in 147 (47%) patients. CKD coding in EMRs was associated with dosage of natraemia (n = 34, 100%, P &amp;lt; 0.01), albuminuria (n = 20, 58%, P &amp;lt; 0.01), vitamin D (n = 14, 41%, P &amp;lt; 0.001), and phosphorus (n = 11, 32%, P &amp;lt; 0.001). Eighty-one patients (31.5%) with low eGFR without an entered code for CKD were prescribed an albuminuria dosage. Clinical monitoring could not be analysed due to poor coding.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This pilot study reinforces the hypothesis that CKD is underscreened and undermanaged. More systematic coding of medical information in EMRs and further studies on medical centre databases should improve primary care practices.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/fampra\/cmad004","type":"journal-article","created":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T09:13:08Z","timestamp":1674897188000},"page":"262-269","source":"Crossref","is-referenced-by-count":1,"title":["Management of patients with chronic kidney disease: a French medical centre database analysis"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5846-0929","authenticated-orcid":false,"given":"Matthieu","family":"Ariza","sequence":"first","affiliation":[{"name":"University of Picardy Jules Verne, Department of General Medicine , Amiens , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Martin","sequence":"additional","affiliation":[{"name":"University of Picardy Jules Verne , Amiens , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2133-8169","authenticated-orcid":false,"given":"Mika\u00ebl","family":"Dusenne","sequence":"additional","affiliation":[{"name":"University Hospital Centre of Rouen , Rouen , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4425-4163","authenticated-orcid":false,"given":"David","family":"Darmon","sequence":"additional","affiliation":[{"name":"University of C\u00f4te d\u2019Azur, RETINES, Department of Teaching and Research in General Medicine , Nice , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7355-4560","authenticated-orcid":false,"given":"Matthieu","family":"Schuers","sequence":"additional","affiliation":[{"name":"Department of General Medicine of Rouen, University of Rouen , Rouen , France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"2024061213165240000_CIT0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-981-13-8871-2_1","article-title":"Prevalence and disease burden of chronic kidney disease","volume":"1165","author":"Lv","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"2024061213165240000_CIT0002","first-page":"s03","article-title":"Chronic kidney disease","volume":"66","author":"Ammirati","year":"2020","journal-title":"Rev Assoc Medica Bras 1992"},{"issue":"9981","key":"2024061213165240000_CIT0003","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(14)61601-9","article-title":"Worldwide access to treatment for end-stage kidney disease: a systematic review","volume":"385","author":"Liyanage","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"83","key":"2024061213165240000_CIT0004","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1046\/j.1523-1755.63.s83.22.x","article-title":"Nephrology in China: a great mission and momentous challenge","volume":"63","author":"Lin","year":"2003","journal-title":"Kidney Int Suppl"},{"issue":"83","key":"2024061213165240000_CIT0005","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1046\/j.1523-1755.63.s83.24.x","article-title":"End-stage renal disease in India and Pakistan: burden of disease and management issues","volume":"63","author":"Sakhuja","year":"2003","journal-title":"Kidney Int Suppl"},{"volume-title":"2021 USRDS annual data report: epidemiology of kidney disease in the United States","year":"2021","author":"United States Renal Data System","key":"2024061213165240000_CIT0006"},{"author":"French National Health Insurance","key":"2024061213165240000_CIT0007"},{"key":"2024061213165240000_CIT0008","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.nephro.2016.02.002","article-title":"[Cost of dialysis in France]","volume":"12","author":"Zambrowski","year":"2016","journal-title":"Nephrol Ther"},{"author":"L\u00e9gifrance","key":"2024061213165240000_CIT0009"},{"issue":"1","key":"2024061213165240000_CIT0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/14789450.2018.1545577","article-title":"Advances in understanding the role of angiotensin-regulated proteins in kidney diseases","volume":"16","author":"Sanz","year":"2019","journal-title":"Expert Rev Proteomics"},{"issue":"1","key":"2024061213165240000_CIT0011","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2215\/CJN.07440618","article-title":"Blood pressure goals in patients with CKD","volume":"14","author":"Chang","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024061213165240000_CIT0012","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","journal-title":"Kidney Int"},{"issue":"1","key":"2024061213165240000_CIT0013","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12877-020-1485-4","article-title":"Medication burden and inappropriate prescription risk among elderly with advanced chronic kidney disease","volume":"20","author":"Roux-Marson","year":"2020","journal-title":"BMC Geriatr"},{"issue":"5","key":"2024061213165240000_CIT0014","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.nephro.2019.07.213","article-title":"La n\u00e9phroprotection en m\u00e9decine g\u00e9n\u00e9rale: pratiques m\u00e9dicales et limites","volume":"15","author":"Fernoux","year":"2019","journal-title":"N\u00e9phrol Th\u00e9r"},{"issue":"9","key":"2024061213165240000_CIT0015","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1001\/archinte.1991.00400090095017","article-title":"Iatrogenic renal disease","volume":"151","author":"Davidman","year":"1991","journal-title":"Arch Intern Med"},{"volume-title":"Chronic kidney disease in the United States, 2021","year":"2021","author":"Centers for Disease Control and Prevention","key":"2024061213165240000_CIT0016"},{"volume-title":"Traitement de l\u2019information M\u00e9dicale Par La Classification Internationale Des Soins Primaires","year":"2000","author":"Jamoulle","key":"2024061213165240000_CIT0017"},{"issue":"1","key":"2024061213165240000_CIT0018","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1590\/2175-8239-jbn-2018-0107","article-title":"Pathophysiological aspects of nephropathy caused by non-steroidal anti-inflammatory drugs","volume":"41","author":"Lucas","year":"2019","journal-title":"J Bras Nefrol"},{"issue":"4","key":"2024061213165240000_CIT0019","doi-asserted-by":"crossref","first-page":"e00817","DOI":"10.1002\/prp2.817","article-title":"Kidney damage from nonsteroidal anti-inflammatory drugs\u2014myth or truth? Review of selected literature","volume":"9","author":"Dro\u017cd\u017cal","year":"2021","journal-title":"Pharmacol Res Perspect"},{"year":"2021","author":"French National Authority for Health","key":"2024061213165240000_CIT0020"},{"issue":"10075","key":"2024061213165240000_CIT0021","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"2024061213165240000_CIT0022","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.nephro.2006.04.007","article-title":"Chronic kidney disease: do generalists and nephrologists differ in their care","volume":"2","author":"Frimat","year":"2006","journal-title":"Nephrol Ther"},{"key":"2024061213165240000_CIT0023","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.arr.2014.02.003","article-title":"The aging kidney revisited: a systematic review","volume":"14","author":"Bolignano","year":"2014","journal-title":"Ageing Res Rev"},{"year":"2022","author":"Centers for Disease Control and Prevention","key":"2024061213165240000_CIT0024"},{"issue":"10","key":"2024061213165240000_CIT0025","doi-asserted-by":"crossref","first-page":"e0205530","DOI":"10.1371\/journal.pone.0205530","article-title":"Modeling the impact of obesity on the lifetime risk of chronic kidney disease in the United States using updated estimates of GFR progression from the CRIC study","volume":"13","author":"Yarnoff","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"2024061213165240000_CIT0026","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s12882-020-02000-7","article-title":"Exploring reasons for state-level variation in incidence of dialysis-requiring acute kidney injury (AKI-D) in the United States","volume":"21","author":"Chen","year":"2020","journal-title":"BMC Nephrol"},{"issue":"3","key":"2024061213165240000_CIT0027","doi-asserted-by":"crossref","first-page":"e0192895","DOI":"10.1371\/journal.pone.0192895","article-title":"Cardiovascular disease risk factors in chronic kidney disease: a systematic review and meta-analysis","volume":"13","author":"Major","year":"2018","journal-title":"PLoS One"},{"issue":"700","key":"2024061213165240000_CIT0028","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.3399\/bjgp20X713105","article-title":"Uncoded chronic kidney disease in primary care: a cross-sectional study of inequalities and cardiovascular disease risk management","volume":"70","author":"Molokhia","year":"2020","journal-title":"Br J Gen Pract"},{"issue":"4","key":"2024061213165240000_CIT0029","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1331\/JAPhA.2014.13195","article-title":"Prescription medication burden in patients with newly diagnosed diabetes: a SUrveillance, PREvention, and ManagEment of Diabetes Mellitus (SUPREME-DM) study","volume":"54","author":"Schmittdiel","year":"2014","journal-title":"J Am Pharm Assoc"},{"issue":"1","key":"2024061213165240000_CIT0030","doi-asserted-by":"crossref","first-page":"e2034059","DOI":"10.1001\/jamanetworkopen.2020.34059","article-title":"A method to quantify mean hypertension treatment daily dose intensity using health care system data","volume":"4","author":"Min","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2024061213165240000_CIT0031","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/ki.2014.74","article-title":"A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use","volume":"86","author":"Blank","year":"2014","journal-title":"Kidney Int"},{"issue":"2","key":"2024061213165240000_CIT0032","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","article-title":"Proton pump inhibitor use and the risk of chronic kidney disease","volume":"176","author":"Lazarus","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"20","key":"2024061213165240000_CIT0033","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.3390\/ijms20205203","article-title":"Adverse effects of proton pump inhibitors-evidence and plausibility","volume":"20","author":"Fossmark","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2024061213165240000_CIT0034","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bcpt.13023","article-title":"Side effects of long-term proton pump inhibitor use: a review","volume":"123","author":"Haastrup","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"2024061213165240000_CIT0035","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/jamia\/ocaa222","article-title":"Renal medication-related clinical decision support (CDS) alerts and overrides in the inpatient setting following implementation of a commercial electronic health record: implications for designing more effective alerts","volume":"28","author":"Shah","year":"2021","journal-title":"J Am Med Inform Assoc"},{"year":"2021","key":"2024061213165240000_CIT0036"},{"year":"2022","author":"French Health Public Agency","key":"2024061213165240000_CIT0037"}],"container-title":["Family Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/fampra\/article-pdf\/41\/3\/262\/58207723\/cmad004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/fampra\/article-pdf\/41\/3\/262\/58207723\/cmad004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T13:28:08Z","timestamp":1718198888000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/fampra\/article\/41\/3\/262\/7008592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,1,27]]},"published-print":{"date-parts":[[2024,6,12]]}},"URL":"https:\/\/doi.org\/10.1093\/fampra\/cmad004","relation":{},"ISSN":["1460-2229"],"issn-type":[{"type":"electronic","value":"1460-2229"}],"subject":[],"published-other":{"date-parts":[[2024,6,1]]},"published":{"date-parts":[[2023,1,27]]}}}